Determine the necessary mass, volume, or concentration for preparing a solution.
JNJ-61803534 - ≥99% , CAS No.1917306-14-9
AVAILABLE TO ORDER
GRADE & PURITY ≥99%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC 50 of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions
In Vitro
JNJ-61803534 inhibits RORγt transcription in HEK-293 T cells transfected with vectors encoding RORγt, with an IC 50 of 9.6 nM. JNJ-61803534 (1 nM-1 μM) inhibits IL-17A, IL-17F IFNγ and IL-22 production in CD4+ T cells isolated from human blood. JNJ-61803534 does not impact in vitro Treg differentiation in CD4+ T cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
JNJ-61803534 (100 mg/kg, p.o.) inhibits ex vivo stimulated IL-17A production in the blood of mice . JNJ-61803534 (3-100 mg/kg BID or 60 mg/kg QD, p.o.) alleviates inflammation, cartilage damage, bone destruction in mouse collagen-induced arthritis (CIA) model . JNJ-61803534 (30 and 100 mg/kg, p.o.) alleviates Imiquimod -induced dermal psoriatic-like inflammation in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mouse collagen-induced arthritis (CIA) model Dosage: 3-100 mg/kg BID or 60 mg/kg QD Administration: Oral administration (p.o.) Result: Decreased clinical arthritis scores and hind paw histopathology scores.
Form:Solid
IC50& Target:RORγt
Specifications
Specifications & Purity
≥99%
Biochemical and Physiological Mechanisms
JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC 50 of 9.6u2009 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions.
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
INHIBITOR
Purity
≥99%
Names and Identifiers
| Molecular Weight | 622.41 |
|---|
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
| Solubility | DMSO : 300 mg/mL (482.00 mM; Need ultrasonic) |
|---|
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.